Floatz logo

Vy-Aadc01

Basal Ganglia Disease

Neurocrine Biosciencesgene_therapyPhase 1Dormant
CC
47/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
32/ 100
Competitive Position
95/ 100

Competitive context

2 Active assets in the Basal Ganglia Disease cohort.

Asset / SponsorPhaseRating
Live Combined Bifidobacterium,Lactobacillus And Enterococcus Capsules
Beijing Friendship Hospital
Phase 4BB
Live Combined Bifidobacterium
Beijing Friendship Hospital
Phase 4BB

Same molecule, other indications

Vy-Aadc01 is also rated in:

Parkinson diseaseDormant
CCC
Indicative ·
52 / 100
View asset →
movement disorderDormant
CC
Indicative ·
47 / 100
View asset →
neurodegenerative diseaseDormant
CC
Indicative ·
47 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →